Amgen Inc.

Malgorzata Wanska

Julio Cesar Medina

Frank Kayser

Xiaoqi Chen

Jeffrey Thomas Mihalic

Zhihua Ma

David John Kopecky

Xiaodong Wang

Richard V Connors

Jeffrey Deignan

Julie Anne Heath

Steven H Olson

Christopher Michael Tegley

Jonathan B Houze

Ning Chen

Xiaohui Du

Zice Fu

Paul John Dransfield

Leslie Phillip Miranda

Vatee Pattaropong

Alan C Cheng

Wen-Chen Yeh

Elizabeth M Doherty

James Richard Falsey

Su-Jen Lai

Gayathri Swaminath

Lars V Heumann

Yinhong Chen

Aarif Yusuf Khakoo

James S Harvey

Jerry Ryan Holder

Justin K Murray

Matthew Irvine Brown

Bin Wu

Nobuko Nishimura

Daqing Sun

Kevin Chao Yang

Matthew R Kaller

Xuelei Yan

Michael G Johnson

Yosup Rew

Felix Gonzalez Lopez De Turiso

Brian M Fox

Michael D Bartberger

Daniel B Horne

John Eksterowicz

Jason A Duquette

Hilary Plake Beck

Ana Zurisadai Gonzalez Buenrostro

Darin J Gustin

Zhihong Li

Kaustav Biswas

Joel McIntosh

Kelvin C Sham

Michael J Schmitt

Jiasheng Fu

Yihong Li

Philip M Roveto

Jason C Long

Kelvin Sham

Christine Weathers

Julio C Medina

Joel Mcintosh

Julie A Heath

Jeffrey T Mihalic

David J Kopecky

Ana Gonzalez Buenrostro

Matthew Brown

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Na1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Na1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

Potent and selective inhibitors of Nav1.7

[object Object]

The present invention provides MDM2 inhibitor compounds of Formula I or II, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer

Growing community of inventors

Camarillo, CA, United States of America

Malgorzata Wanska